Outcomes among patients with non-ST-elevation myocardial infarction on chronic anticoagulation: Insights from the National Inpatient Sample.
National Inpatient Sample (NIS)
acute coronary syndrome (ACS)
bleeding complications
chronic anticoagulation
inpatient mortality
non‐ST‐elevation myocardial infarction (NSTEMI)
patient outcomes
stroke
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
28
07
2024
received:
08
07
2024
accepted:
10
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Chronic systemic anticoagulation use is prevalent for various thromboembolic conditions. Anticoagulation (usually through heparin products) is also recommended for the initial management of non-ST-elevation myocardial infarction (NSTEMI). To evaluate the in-hospital outcomes of patients with NSTEMI who have been on chronic anticoagulation. Using the National Inpatient Sample (NIS) years 2016-2020, NSTEMI patients and patients with chronic anticoagulation were identified using the appropriate International Classification of Diseases, 10th version (ICD-10) appropriate codes. The primary outcome was all-cause in-hospital mortality while the secondary outcomes included major bleeding, ischemic cerebrovascular accident (CVA), early percutaneous coronary intervention (PCI) (i.e., within 24 h of admission), coronary artery bypass graft (CABG) during hospitalization, length of stay (LOS), and total charges. Multivariate logistic or linear regression analyses were performed after adjusting for patient-level and hospital-level factors. Among 2,251,914 adult patients with NSTEMI, 190,540 (8.5%) were on chronic anticoagulation. Chronic anticoagulation use was associated with a lower incidence of in-hospital mortality (adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.65-0.73, p < 0.001). There was no significant difference in major bleeding (aOR: 0.95, 95% CI: 0.88-1.0, p = 0.15) or ischemic CVA (aOR: 0.23, 95% CI: 0.03-1.69, p = 0.15). Chronic anticoagulation use was associated with a lower incidence of early PCI (aOR: 0.78, 95% CI: 0.76-0.80, p < 0.001) and CABG (aOR: 0.43, 95% CI: 0.41-0.45, p < 0.001). Chronic anticoagulation was also associated with decreased LOS and total charges (adjusted mean difference [aMD]: -0.8 days, 95% CI: -0.86 to -0.75, p < 0.001) and (aMD: $-19,340, 95% CI: -20,692 to -17,988, p < 0.001). Among patients admitted with NSTEMI, chronic anticoagulation use was associated with lower in-hospital mortality, LOS, and total charges, with no difference in the incidence of major bleeding.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic systemic anticoagulation use is prevalent for various thromboembolic conditions. Anticoagulation (usually through heparin products) is also recommended for the initial management of non-ST-elevation myocardial infarction (NSTEMI).
AIMS
OBJECTIVE
To evaluate the in-hospital outcomes of patients with NSTEMI who have been on chronic anticoagulation.
METHODS
METHODS
Using the National Inpatient Sample (NIS) years 2016-2020, NSTEMI patients and patients with chronic anticoagulation were identified using the appropriate International Classification of Diseases, 10th version (ICD-10) appropriate codes. The primary outcome was all-cause in-hospital mortality while the secondary outcomes included major bleeding, ischemic cerebrovascular accident (CVA), early percutaneous coronary intervention (PCI) (i.e., within 24 h of admission), coronary artery bypass graft (CABG) during hospitalization, length of stay (LOS), and total charges. Multivariate logistic or linear regression analyses were performed after adjusting for patient-level and hospital-level factors.
RESULTS
RESULTS
Among 2,251,914 adult patients with NSTEMI, 190,540 (8.5%) were on chronic anticoagulation. Chronic anticoagulation use was associated with a lower incidence of in-hospital mortality (adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.65-0.73, p < 0.001). There was no significant difference in major bleeding (aOR: 0.95, 95% CI: 0.88-1.0, p = 0.15) or ischemic CVA (aOR: 0.23, 95% CI: 0.03-1.69, p = 0.15). Chronic anticoagulation use was associated with a lower incidence of early PCI (aOR: 0.78, 95% CI: 0.76-0.80, p < 0.001) and CABG (aOR: 0.43, 95% CI: 0.41-0.45, p < 0.001). Chronic anticoagulation was also associated with decreased LOS and total charges (adjusted mean difference [aMD]: -0.8 days, 95% CI: -0.86 to -0.75, p < 0.001) and (aMD: $-19,340, 95% CI: -20,692 to -17,988, p < 0.001).
CONCLUSIONS
CONCLUSIONS
Among patients admitted with NSTEMI, chronic anticoagulation use was associated with lower in-hospital mortality, LOS, and total charges, with no difference in the incidence of major bleeding.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Khera S, Kolte D, Aronow WS, et al. Non‐ST‐elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in‐hospital outcomes. J Am Heart Assoc. 2014;3(4):e000995. doi:10.1161/JAHA.114.000995
Basit H, Malik A, Huecker MR. Non–ST‐Segment Elevation Myocardial Infarction. StatPearls [Internet]. StatPearls Publishing; 2023.
Joglar JA, Chung MK, Armbruster AL, et al. ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;2024(149):e1‐e156.
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693‐4738.
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease. Chest. 2021;160:e545‐e608.
Gandhi S, Garratt KN, Li S, et al. Ten‐year trends in patient characteristics, treatments, and outcomes in myocardial infarction from national cardiovascular data registry chest pain‐MI registry. Circ Cardiovasc Qual Outcomes. 2022;15:e008112.
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720‐3826.
Lip GYH, Collet J‐P, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) Endorsed by the Heart Rhythm Society (HRS), Asia‐Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21:192‐193.
Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI. J Am Coll Cardiol. 2019;74:83‐99.
Huang Y‐M, Shih H‐J, Chen Y‐C, et al. Systemic anticoagulation and inpatient outcomes of pancreatic cancer: real‐world evidence from U.S. Nationwide Inpatient Sample. Cancers. 2023;15(7):1985. doi:10.3390/cancers15071985
Elbaz‐Greener G, Rozen G, Kusniec F, et al. Trends in utilization and safety of in‐hospital coronary artery bypass grafting during a non‐ST‐segment elevation myocardial infarction. Am J Cardiol. 2020;134:32‐40.
Isogai T, Saad AM, Ahuja KR, et al. Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. Catheter Cardiovasc Interv. 2022;99:877‐888.
Edigin E, Ojemolon PE, Eseaton PO, et al. Systemic sclerosis is associated with increased inpatient mortality in patients admitted for acute coronary syndrome: analysis of the National Inpatient Sample. J Clin Rheumatol. 2022;28:e110‐e117.
Dewilde WJM, Janssen PW, Kelder JC, et al. Uninterrupted oral anticoagulation versus bridging in patients with long‐term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 2015;11:381‐390.
Kowalewski M, Suwalski P, Raffa GM, et al. Meta‐analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. Int J Cardiol. 2016;223:186‐194.
De Luca L, Rubboli A, Bolognese L, et al. Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes? Open Heart. 2021;8:e001677. doi:10.1136/openhrt-2021-001677